Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Expecting 1st child together
Shoplifter sets clerk on fire?
Two children drown in pool
Settles assault lawsuit
Bear attacks 73-year-old
Violated False Claims Act
Illinois migrant crisis
Leaves with concussion
Philly: Alleged shooter killed
WA raises minimum wage
US fines Stanford $2M
Targets $9.2B valuation
Govt. sues Union Pacific
Gets trailer, premiere date
29 soldiers killed in Niger
OKs 2nd malaria vaccine
Angels split with Nevin
Open to bless gay couples?
Five-year, $146M extension
Honored w/ postage stamp
Barred from Rockets
'Age is just a number'
Facing defamation lawsuit
3-year contract extension
Get married in Italy
Carjacked at gunpoint
Sentenced to 3 yrs probation
Ex-CEO used men for sex?
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
172,000 results
WISH-TV
5d
Health Spotlight: First FDA-approved drug to slow Alzheimer’s
More than 6,000,000 Americans are living with Alzheimer's disease – it slowly steals your memories and takes away your mind ...
朝日新聞社14d
Alzheimer’s drug Leqembi has full FDA approval
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...
12don MSN
Medical Moment: FDA approves first-ever drug to slow Alzheimer’s
There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
朝日新聞社5d
US approves Alzheimer’s drug that modestly slows disease
FDA approves much-debated Alzheimer’s drug panned by experts June 8, 2021 Alzheimer’s drug from Eisai and Biogen slows cognitive decline, side-effects in focus ...
4d
FDA advisers vote against experimental ALS treatment pushed by patients
The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not ...
Forbes22d
What To Know About The Alzheimer’s Drug Leqembi
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
7don MSN
After US approval, Japan approves Leqembi, its first Alzheimer's drug
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
3don MSN
FDA wants to regulate thousands of lab tests that have long skirted oversight
The Food and Drug Administration says it plans to begin regulating laboratory-based medical tests. It's a multibillion-dollar ...
The Financial Times29d
Vivek Ramaswamy’s FDA ‘corruption’ claims disavowed by Roivant
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
WTOP News19d
New Treatments for Alzheimer’s Disease
For anyone who has or knows someone who has Alzheimer’s disease, a progressive and irreversible form of dementia that’s ultimately deadly, it can sometimes be difficult to find hope.
1don MSN
Alzheimer’s Association makes progress on treating Alzheimer’s and dementia
Progress is being made in treating Alzheimer’s and Dementia, one individual with the Alzheimer's Association is optimistic that a full treatment could be available within her lifetime.
7d
After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices